bioRxiv Science⌕ Search

bioRxiv · 10.1101/2022.03.16.484601

Feature selection and aggregation for antibiotic resistance GWAS in Mycobacterium tuberculosis: a comparative study.

Abstract

Drug resistance (DR) remains a global healthcare concern. In contrast to other human bacterial pathogens, acquiring mutations in the genome is the main mechanism of drug resistance for Mycobacterium tuberculosis (MTB). For some antibiotics resistance of a particular isolate can be predicted with high confidence knowing whether specific mutations occurred, but for some antibiotics our knowledge of resistance mechanism is moderate. Statistical machine learning (ML) methods are used in attempts to infer new genes implicated in drug resistance. These methods use large collections of isolates with known whole-genome sequences and resistance status for different drugs. However, high correlations between the presence or absence of resistance to drugs that are used together in one treatment regimen complicate inference of causal mutations by traditional ML. Recently, several new methods were suggested to deal with the problem of correlations of response variables in training data. In this study, we applied the following methods to tackle the confounding effect of resistance co-occurrence in a dataset of approximately 13 000 complete genomes of MTB with characterized resistance status for 13 drugs: logistic regression with different regularization penalty functions, a polynomial-time algorithm for best-subset selection problem (ABESS), and "Hungry, Hungry SNPos" (HHS) method. We compared these methods by the ability to select known causal mutations for the resistance to each particular drug and not to select mutations in genes that are known to be associated with resistance to other drugs. ABESS significantly outperformed the others selecting more relevant sets of mutations. We also showed that aggregation of rare mutations into features indicating changes of PFAM domains increased the quality of prediction and these features were majorly selected by ABESS. Impact statementDue to the high significance of the problem, many studies in the recent decade aimed to predict drug susceptibility/resistance of MTB from its genotype. Most of such methods were based on prior biological knowledge, e.g. consideration of mutations occurring in known genes involved in the metabolism of drugs. In our study, we estimated to what extent ML methods could extract de novo biologically relevant associations of mutations with resistance/susceptibility to drugs from large datasets of clinical MTB isolates. As a criterion of accuracy we used the known experimentally verified associations of mutations in MTB genes to corresponding drugs. The most accurate approach from the benchmarked ones addressed the most of these known genes to proper drugs. The result of feature selection was robust despite the presence of population structure with strong phylogenetic and geographic signals in the dataset. Also, we designed an original approach for aggregation of rare mutations and demonstrated that it improved classification accuracies of ML models. To our knowledge, this study is the first comparison of modern feature selection methods applied to genome-wide association studies (GWAS) of MTB drug resistance. Data SummaryThe dataset unifies characterized whole-genome sequences of M. tuberculosis from multiple studies [1-10]. Short Illumina reads are available in public repositories (SRA or ENA). Sample ids, phenotypes and links to the source papers are summarized and listed in Table S1. The dataset and the source code can be downloaded from the GitHub repository: https://github.com/Reshetnikoff/m.tuberculosis-research-code

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Reshetnikov, K. O., Bykova, D. I., Kuleshov, K. V., Chukreev, K., Guguchkin, E. P., Akimkin, V. G., Neverov, A. D., Fedonin, G. G.. 2022-03-18. Feature selection and aggregation for antibiotic resistance GWAS in Mycobacterium tuberculosis: a comparative study.. https://doi.org/10.1101/2022.03.16.484601

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

mFrag: Integrating External DNA Methylation References Improves Lung Cancer Early Detection by Fragmentomics

Fragmentomics analyzes features of circulating cell-free DNA fragments (e.g., fragment length or end motifs) derived from whole-genome sequencing of liquid biopsy samples (blood or other body fluids), enabling non-invasive early cancer detection. Here we present mFrag, a framework that integrates external methylation reference atlases with fragmentomic features for lung cancer detection. mFrag comprises two complementary methods: mFrag-Weight, which uses DNA methylation information to weight fragmentomic features, and mFrag-Net, which integrates fragmentomic features and external DNA methylation data through neural networks. We average the output probabilities of the two methods to obtain a final prediction score. The mFrag model was trained using 287 individuals at risk for lung cancer. In an independent case-control testing set comprising 385 non-cancer controls and 46 cancers (28 stage I, 12 stage II, and 6 stage III or IV), mFrag outperforms a DELFI-style fragmentomic approach, improving PR-AUC from 0.455 to 0.720 and sensitivity at 99% specificity from 0.043 to 0.478, with ROC-AUC from 0.871 to 0.908. For stage I lung cancer, mFrag raises PR-AUC from 0.314 to 0.558 and ROC-AUC from 0.855 to 0.894. Applied to end 4-mer motif features, mFrag likewise improved over an unweighted baseline, with gains contributed by both mFrag-Weight and mFrag-Net. In summary, mFrag improves the accuracy of fragmentomics-based lung cancer detection through integrating external DNA methylation data and the complementarity of its two component models, without incurring any additional data-generating cost.

bioinformatics↗

AOPTK: Open-Source Software for AI-Assisted Toxicological Literature Analysis

Motivation: Toxicologists today face a challenge: although vast amounts of data describing how chemicals affect human health are available across scientific publications and regulatory reports, much of this information remains underutilized because extracting and interpreting evidence across thousands of studies is impractical to perform manually. Recent advances in artificial intelligence (AI), particularly in large language models (LLMs), provide new opportunities to automate toxicological literature analysis. Results: Herein, we present the Adverse Outcome Pathway Toolkit (AOPTK), an open-source Python package for AI-enhanced analysis of toxicological and biomedical literature. AOPTK supports (i) automated literature retrieval from databases such as PubMed Central and Europe PMC, (ii) direct processing of full-text articles in PDF format, and (iii) LLM-assisted analysis tools to identify chemicals and extract their relationships to biological effects under user-defined conditions. We demonstrate its utilities through a case-study identifying potential non-genotoxic carcinogens based on their ability to inhibit gap junction intercellular communication (GJIC). The LLM-enhanced analysis achieves 81% agreement with an expert-curated inhibitor list and 95% accuracy in predicting inhibition versus no inhibition when analysing the same subset of 86 publications. Automated retrieval and analysis of 1 124 publications from PubMed Central further demonstrated the feasibility of applying AOPTK to large-scale literature analyses. Availability: The package is developed open source on GitHub, disseminated through PyPI and Bioconda and releases are archived on Zenodo. Individual tools are available in the Galaxy platform for accessible data analysis with user-friendly, findable, accessible, interoperable, and reusable (FAIR) and end-to-end workflows provided via WorkflowHub. The tools are available on usegalaxy.eu and usegalaxy.cz and are developed open source on GitHub.

bioinformatics↗

MELD: Mutation Effect Learning through Differential embeddings

We introduce MELD (Mutation Effect Learning through Differential Embeddings), a compact model for predicting the functional consequences of single nucleotide variants (SNVs) by training directly on the wild-type (WT) versus mutant differential. Interpreting SNVs is central to clinical genomics, yet experimental characterization cannot scale to millions of observed variants. Leading sequence-to-function models (Enformer, Borzoi, AlphaGenome) are trained on absolute genomic tracks and score variants post hoc through in-silico mutagenesis (ISM), so the WT-mutant difference never enters the training loss. MELD instead places the logit difference {Delta}z = zmut - zwt inside the supervised objective. It combines a shared CNN-Transformer encoder, a mutant-specific mutation-mask boost, multiscale mutation-centered pooling, and a learned adaptive amplification factor . On ClinVar (1.57M variants), MELD (1.9M parameters) reached an AUROC of 0.986 versus 0.800 for a same-data, same-backbone ISM baseline, with ablations confirming the contribution of each component. On a shared benchmark, it outperformed frozen foundation models with 3-1,300x more parameters (AUROC 0.967 vs. 0.924 for AlphaGenome and 0.936 for Nucleotide Transformer). With only 50, 000 training variants, it exceeded the ISM baseline trained on all 1.48M (AUROC 0.903 vs. 0.796) variants. On BRCA1 saturation genome editing, frozen MELD achieved a Spearman {rho} of 0.42, above Borzoi (0.40), and ClinVar transfer raised it to 0.45. These results demonstrate that direct differential supervision is a compact, data-efficient alternative to post-hoc ISM scoring with substantially larger pretrained models.

bioinformatics↗